As a practicing physician who also specializes in caring for patients injured in motor vehicle accidents, I’ve seen firsthand how complex and emotionally charged these situations can be. Over the years, I’ve treated people with devastating, life-changing injuries from crashes, as well as those with subtler but still very real problems like persistent pain, spinal issues, or concussions that develop over time. At the same time, I’ve witnessed the intricate medical-legal system that helps patients recover financially while sometimes creating its own challenges. Here’s a clear, balanced overview of the current tensions involving Uber, drawing only on information from public reports.

Lien-based treatment: a double-edged sword

Many accident victims, particularly those without immediate health insurance or savings, depend on lien-based care. Doctors and clinics agree to treat patients now and seek payment later from any settlement. This approach often enables timely care for soft-tissue injuries, disc problems, concussions, and other conditions that may not be obvious right away. For details on personal injury work in pain management, you can refer to Chapter 18 of the book Legal Mind in Medicine.

That said, the system can sometimes create incentives for extended treatment or higher billing. Insurers watch these cases closely, and interpretations of what counts as necessary care can vary widely. In my view, the goal should always be medically appropriate treatment backed by solid documentation, nothing more and nothing less.

Uber’s federal RICO lawsuits

Since mid-2025, Uber has filed several federal civil Racketeer Influenced and Corrupt Organizations Act (RICO) lawsuits against certain personal injury law firms, attorneys, and associated medical providers in states like California, New York, Florida, and Pennsylvania. Uber alleges that some attorneys and medical networks direct clients, often from relatively minor Uber accidents, to specific providers for treatments that may be unnecessary (such as certain spinal injections or ablations). They claim bills are inflated through liens, with “side agreements” used to strategically adjust amounts in order to maximize payouts under Uber’s $1 million rideshare insurance policies.

Notable cases include suits targeting firms like the Downtown LA Law Group and attorney Jacob Emrani in Los Angeles (around July 2025), among others. Uber describes alleged kickback-style arrangements and “phantom damages,” arguing these tactics turn low-value claims into high-value ones.

Uber’s position

These actions combat real insurance fraud and inflated claims that raise costs for everyone. RICO allows for significant penalties (including treble damages) and is meant to deter such behavior.

A medical perspective

Legitimate diagnostic testing and treatment are crucial for properly documenting injuries and supporting recovery. Over-treatment can expose patients to unnecessary risks and erode public trust. At the same time, broad lawsuits naming providers can make ethical doctors think twice about accepting lien cases from rideshare accidents. This hesitation risks delaying care for patients who genuinely need it, as clinicians weigh the added litigation risks and costs. These cases are still ongoing as of May 2026, with some dismissal efforts underway.

The California ballot initiative

Uber is also supporting a proposed constitutional amendment (filed around October 2025 and now in the signature-gathering phase) often referred to as the “Protecting Automobile Accident Victims from Attorney Self-Dealing Act.” Importantly, this would apply to all vehicle crashes in California, not just those involving Uber. Supporters’ view, including Uber’s, is that this protects consumers from excessive attorney fees and puts more money directly into victims’ pockets while curbing inflated medical billing. The main provisions, based on reports, include:

• Caps on contingency fees for plaintiff attorneys in auto cases (structured so victims might retain at least 75 percent after costs and liens).
• Limits on how much can be recovered for medical costs and damages.
• Defense-side legal fees (e.g., Uber’s) would remain uncapped.

Opposition from attorneys and some medical groups

They argue the changes could make many moderate or complex cases unprofitable for lawyers, who often front substantial costs for experts, imaging, and investigations. As a result, victims, especially those going against large corporations, might struggle to find representation, leading to lower settlements or abandoned claims. Evidence from comments and statements:

• Doug Saeltzer, president of Consumer Attorneys of California: “Uber wrote it to be expansive, to keep victims from finding attorneys.”
• Stanford law professor and others: The initiative won’t protect victims but will “muzzle them” by locking poorer plaintiffs out of the courthouse, as contingency fees enable access to justice against deep-pocketed defendants like Uber.
• Plaintiff attorney commentary: Lower fees and medical limits mean “fewer plaintiff lawyers willing to take Uber accident cases,” reducing pressure on Uber to pay fair compensation.

It would require roughly 875,000 signatures by mid-2026 to reach the November 2026 ballot. Both sides are investing heavily in the campaign.

Plaintiff-side response

Many defendants call these suits baseless intimidation tactics designed to chill legitimate claims against a deep-pocketed corporation. Critics argue they threaten access to justice for genuine injury victims by making attorneys wary of taking Uber cases. These cases are ongoing as of early 2026; outcomes could influence similar actions by other insurers or defendants.

• Rideshare specifics: Uber faces many claims due to its scale, mandatory high insurance limits in some states, and driver classification issues. Legitimate cases (e.g., passenger injuries, assaults) continue, but fraud allegations have intensified scrutiny.
• Effects: Increased pressure on practices or lien-based medical referrals are common in personal injury. This could raise the bar for case acceptance, documentation, and provider relationships industry-wide. Some see it as part of a larger corporate pushback on tort liability.
• Counter-moves: Plaintiff groups have proposed their own initiatives to expand Uber’s liability (e.g., for passenger injuries or misconduct).

Broader context and patient impact

Fraud and exaggerated claims do happen, and they hurt everyone by driving up premiums, straining insurance systems, and creating skepticism toward patients with legitimate injuries. Uber’s efforts shine a light on problematic referral practices in some networks.

On the other hand, countless car accident victims experience verifiable harm, including whiplash, disc herniations, fractures, and PTSD, that requires coordinated medical and legal support. When the system works well, strong collaboration between providers and attorneys helps document injuries fairly so patients can heal without financial devastation. Changes that go too far in deterring quality representation or treatment could leave many genuine victims under-compensated or without timely care.

Plaintiff-side voices often describe the RICO suits as intimidation tactics aimed at discouraging legitimate claims against a powerful company. Rideshare cases are common due to Uber’s size, insurance requirements, and driver status issues. Legitimate claims involving passenger injuries or assaults continue, but the fraud allegations have increased overall scrutiny. Some see this as part of a wider corporate effort to limit tort liability, while plaintiff groups have proposed competing measures to strengthen accountability.

Questions about focus and timing

Some advocates and safety groups suggest Uber’s strong push on these personal injury issues may also serve to divert attention from its significant challenges with driver-related sexual misconduct. Uber faces a large multidistrict litigation (MDL) with over 3,300 cases as of April 2026, involving claims of inadequate screening, ignored warnings, and failure to protect passengers. Early bellwether trials have resulted in verdicts against the company, including an $8.5 million award. Uber’s core strategy relies on the independent contractor classification for their drivers to limit vicarious liability, but it is not a complete shield, especially in California for active rides or when corporate negligence can be shown. This classification is central to why Uber is fighting hard on personal injury. Competing ballot efforts aim to impose stricter safety standards and liability on rideshare companies. Whether the timing is coincidental or strategic, the overlap with safety scrutiny is notable.

While Uber’s official complaints focus on alleged fraud, kickbacks, unnecessary treatments, and inflated liens rather than marketing per se, articles note Uber is “taking aim at the bottom lines of billboard lawyers” and targeting firms known for high-volume practices and advertising that they actively sue Uber (leveraging the $1 million insurance policies). As mentioned above, some plaintiff-side voices view these suits as part of a strategy to deter the attorneys who most aggressively pursue large recoveries against Uber and other deep-pocketed defendants.

My take as a clinician

The best outcome for patients is accountability across the board: strong measures against real fraud paired with safeguards that don’t discourage legitimate care or representation. Patients recover best with transparent, evidence-based medicine, ethical legal support, and a system that promotes early, appropriate intervention. I always encourage prioritizing documented medical necessity, independent evaluations, and full regulatory compliance.

Update as of May 2026

The RICO suits remain active with potential for settlements or precedent-setting rulings. The ballot fight is heating up, with signature gathering underway and heavy campaigning on both sides. No final resolution yet on the initiative. Outcomes could reshape personal injury economics in California and inspire similar efforts elsewhere. This remains highly contentious. Uber maintains it is fighting real fraud to protect consumers and control costs. Opponents see a powerful corporation using legal and political tools to tilt the scales against injured individuals and their advocates. The RICO cases are ongoing (with some motions and amendments as of early 2026), and the ballot fight is expensive and active. These are complex issues with points on multiple sides. It is worth mentioning that this statement is general information drawn from public reports, and it is not personalized with medical or legal inclination.

Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.

Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.

Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.